Literature DB >> 28980211

Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.

Suguru Yamashita1, Michael J Overman2, Huamin Wang3, Jun Zhao3, Masayuki Okuno1, Claire Goumard1, Ching-Wei Tzeng1, Michael Kim1, Jason B Fleming1, Jean-Nicolas Vauthey1, Matthew H Katz1, Jeffrey E Lee1, Claudius Conrad4.   

Abstract

BACKGROUND: The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established.
METHODS: A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (≥ 50% of viable residual tumor cells). Uni- and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS).
RESULTS: For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS.
CONCLUSION: The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.

Entities:  

Mesh:

Year:  2017        PMID: 28980211      PMCID: PMC6039188          DOI: 10.1245/s10434-017-6098-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  38 in total

1.  Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy.

Authors:  Edwin O Onkendi; Sarah Y Boostrom; Michael G Sarr; Michael B Farnell; David M Nagorney; John H Donohue; Michael L Kendrick; Kaye M Reid Lombardo; Michael G Haddock; Florencia G Que
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

2.  Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.

Authors:  Han Sang Kim; Sang Jun Shin; Joo-Hang Kim; Hyunki Kim; Hye Jin Choi
Journal:  Tohoku J Exp Med       Date:  2013-09       Impact factor: 1.848

3.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  Predictors of Survival in Ampullary, Bile Duct and Duodenal Cancers Following Pancreaticoduodenectomy: a 10-Year Multicentre Analysis.

Authors:  Stéphane Bourgouin; Jacques Ewald; Julien Mancini; Vincent Moutardier; Jean-Robert Delpero; Yves-Patrice Le Treut
Journal:  J Gastrointest Surg       Date:  2015-05-07       Impact factor: 3.452

5.  The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.

Authors:  Stefano Cereda; Paolo Passoni; Michele Reni; Maria G Viganò; Luca Aldrighetti; Roberto Nicoletti; Eugenio Villa
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

6.  Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.

Authors:  Manisha Palta; Pretesh Patel; Gloria Broadwater; Christopher Willett; Joseph Pepek; Douglas Tyler; S Yousuf Zafar; Hope Uronis; Herbert Hurwitz; Rebekah White; Brian Czito
Journal:  Ann Surg Oncol       Date:  2011-11-02       Impact factor: 5.344

7.  Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study.

Authors:  Rosa Autorino; Gian Carlo Mattiucci; Francesco Ardito; Mario Balducci; Francesco Deodato; Gabriella Macchia; Giovanna Mantini; Vincenzo Perri; Andrea Tringali; Maria Antonietta Gambacorta; Luca Tagliaferri; Felice Giuliante; Alessio Giuseppe Morganti; Vincenzo Valentini
Journal:  Anticancer Res       Date:  2016-02       Impact factor: 2.480

8.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Gauri R Varadhachary; Robert A Wolff; Hua Wang; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Christopher Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Cancer       Date:  2011-10-25       Impact factor: 6.860

9.  Survival in ampullary cancer: potential role of different KRAS mutations.

Authors:  Nakul P Valsangkar; Thun Ingkakul; Camilo Correa-Gallego; Mari Mino-Kenudson; Ricard Masia; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Andrew S Liss; Sarah P Thayer
Journal:  Surgery       Date:  2015-02       Impact factor: 3.982

10.  Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Authors:  Michael J Overman; Gauri R Varadhachary; Scott Kopetz; Rosni Adinin; E Lin; Jeffrey S Morris; Cathy Eng; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.